232 related articles for article (PubMed ID: 31152787)
1. Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials.
Zuo Y; Li T; Lei Z
Pharmacol Res; 2019 Aug; 146():104286. PubMed ID: 31152787
[TBL] [Abstract][Full Text] [Related]
2. Improving renoprotective effects by adding piperazine ferulate and angiotensin receptor blocker in diabetic nephropathy: a meta-analysis of randomized controlled trials.
Yang C; Yang W; Chen Y; Cheng Q; Chen W
Int Urol Nephrol; 2022 Feb; 54(2):299-307. PubMed ID: 34191230
[TBL] [Abstract][Full Text] [Related]
3. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Efficacy of Piperazine Ferulate Combined With Irbesartan in Diabetic Nephropathy: A Systematic Review and Meta-analysis.
Li D; Li B; Peng LX; Liu R; Zeng N
Clin Ther; 2020 Nov; 42(11):2196-2212. PubMed ID: 33158581
[TBL] [Abstract][Full Text] [Related]
5. [Systematic review on sodium ferulate for treatment of diabetic nephropathy].
Yin H; Yan X; Yang KH
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Nov; 29(11):970-4. PubMed ID: 20329603
[TBL] [Abstract][Full Text] [Related]
6. Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
Chen Y; Liu P; Chen X; Li Y; Zhang F; Wang Y
Am J Med Sci; 2018 May; 355(5):418-424. PubMed ID: 29753370
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tripterygium glycosides combined with ARB on diabetic nephropathy: a meta-analysis.
Wu X; Huang Y; Zhang Y; He C; Zhao Y; Wang L; Gao J
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33057690
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
Shen X; Zhang Z; Zhang X; Zhao J; Zhou X; Xu Q; Shang H; Dong J; Liao L
Lipids Health Dis; 2016 Oct; 15(1):179. PubMed ID: 27733168
[TBL] [Abstract][Full Text] [Related]
9. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Beer C; Blacker D; Bynevelt M; Hankey GJ; Puddey IB
Int J Stroke; 2012 Feb; 7(2):104-11. PubMed ID: 22044557
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
[TBL] [Abstract][Full Text] [Related]
11. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
[TBL] [Abstract][Full Text] [Related]
12. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
13. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
14. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Pohl MA; Blumenthal S; Cordonnier DJ; De Alvaro F; Deferrari G; Eisner G; Esmatjes E; Gilbert RE; Hunsicker LG; de Faria JB; Mangili R; Moore J; Reisin E; Ritz E; Schernthaner G; Spitalewitz S; Tindall H; Rodby RA; Lewis EJ
J Am Soc Nephrol; 2005 Oct; 16(10):3027-37. PubMed ID: 16120823
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of antiplatelet drugs for the prevention of diabetic nephropathy: A meta-analysis of randomized controlled trials
.
Chen G; Huang W; Hong S; Li X; Su B; Li X; Tang S
Clin Nephrol; 2018 Dec; 90(6):419-426. PubMed ID: 30378535
[TBL] [Abstract][Full Text] [Related]
16. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials.
Li GM; Zhao J; Li B; Zhang XF; Ma JX; Ma XL; Liu J
Autoimmun Rev; 2018 Mar; 17(3):215-225. PubMed ID: 29353098
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
18. Xuebijing injection combined with alprostadil in the treatment of diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis.
Hao N; Liu Y; Guo L; Li W; Zhao P
Medicine (Baltimore); 2024 Jun; 103(24):e32095. PubMed ID: 38875385
[TBL] [Abstract][Full Text] [Related]
19. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
Zhao XM; Zhang Y; He XH; Chen HD; Wang ZF; Guo J; Wang XM; Gao ZZ; Wang JP; Liu W; Zhao LH; Tong XL
Trials; 2018 Mar; 19(1):200. PubMed ID: 29587863
[TBL] [Abstract][Full Text] [Related]
20. Statins influence biomarkers of low grade inflammation in apparently healthy people or patients with chronic diseases: A systematic review and meta-analysis of randomized clinical trials.
Milajerdi A; Larijani B; Esmaillzadeh A
Cytokine; 2019 Nov; 123():154752. PubMed ID: 31228727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
